

LOBBYING REPORT

00 AUG 11 PM 2:32

Lobbying Disclosure Act of 1995 (Section 5) - All Filers are Required to Complete This Page

1. Registrant Name Capitol Associates, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 426 C Street, NE, Washington, DC 20002			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Debra M. Hardy Havens	Telephone (202) 544-1880	E-mail (optional) dh@capitolassociates.com	5. Senate ID # 8101-277
7. Client Name Glaxo Wellcome, Inc.	<input type="checkbox"/> Self		6. House ID # 30813023

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ Termination Date \_\_\_\_\_ 11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<b>12. Lobbying Firms</b>  INCOME relating to lobbying activities for this reporting period was:  Less than \$10,000 <input type="checkbox"/>  \$10,000 or more <input checked="" type="checkbox"/> <u>\$ 100,000</u> Income (nearest \$20,000)  Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>13. Organizations</b>  EXPENSES relating to lobbying activities for this reporting period were:  Less than \$10,000 <input type="checkbox"/>  \$10,000 or more <input type="checkbox"/> = <u>5</u> Expenses (nearest \$20,000)  <b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See Instructions for description of options.  <input type="checkbox"/> Method A. Reporting amounts using LDA definitions only  <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature Debra M. Hardy Havens

Printed Name and Title Debra M. Hardy Havens, CEO

Registrant Name Capitol Associates, Inc. Client Name Glaxo Wellcome, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

Funding for medical research at the NIH and drug evaluation at the FDA.

H.R. 4461- Making appropriations for Agriculture, Rural Development, Food and Drug Administration and Related Agencies programs for the fiscal year ending September 30, 2001, and for other purposes; Title VI- tracked, monitored, reported consideration of legislation.

S. 2536- An original bill making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2001, and for other purposes; Title VI- tracked, monitored, reported consideration of legislation.

H.R. 4577- Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2001, and for other purposes; Title II- tracked, monitored, reported consideration of legislation, including amendments relative to "reasonable pricing," and funding relative to ADAP.

S. 2553- An original bill making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2001, and for other purposes; Title II- tracked, monitored, reported consideration of legislation, including amendments relative to "reasonable pricing," and funding relative to ADAP.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Ed Long		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Registrant Name Capitol Associates, Inc. Client Name Glaxo Wellcome, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

H.R. 1388/S. 784, Medicare Cancer Clinical Trial Coverage Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 2621, Pediatric Research Initiative Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 3110, Dr. Sydney E. Salmon Access to Cancer Research Clinical Trials Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 4605, Human Research Subjects Protections Act of 2000 -- tracked, monitored, reported consideration of legislation.

S. 1010, Medical Innovation Tax Credit for Clinical Testing Research -- tracked, monitored, reported consideration of legislation.

H.R. 1057, Medical Information Privacy Act -- tracked, monitored, reported consideration of legislation.

H.R. 1941, Health Information Privacy Act -- tracked, monitored, reported consideration of legislation.

H.R. 2404, Personal Medical Information Protection Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 2457/S. 1322, Genetic Nondiscrimination in Health Insurance and Employment Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 2470, Medical Information Protection and Research Enhancement Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 2878, Medical Privacy in the Age of New Technologies Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 4585, Medical Financial Privacy Protection Act -- tracked, monitored, reported consideration of legislation.

S. 573, Medical Information Privacy and Security Act -- tracked, monitored, reported consideration of legislation.

Tracked and monitored rule-making process for medical records privacy.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House

Senate

Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Tricia Brooks		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Registrant Name Capitol Associates, Inc. Client Name Glaxo Wellcome, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

H.R. 434, H. Res. 250, H. Res. 488, H. Res. 489, S. Con. Res. 112, S. 1387 -- Africa Free Trade Bill -- tracked, monitored, and reported consideration of legislation

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Form LD-2 (Rev. 06/98)

PAGE 4 of 5

Registrant Name Capitol Associates, Inc. Client Name Glaxo Wellcome, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code HRC (one per page)

16. Specific lobbying issues

S. 805, Children's Asthma Relief Act of 1999 - tracked, monitored, reported consideration of legislation.

S. Amdt. 2286 to S. 1650, to increase funds for CDC to provide grants regarding childhood asthma - tracked, monitored, reported consideration of legislation.

S. Amdt. 3708 to H.R. 4577, to increase funds for CDC to provide grants regarding childhood asthma - tracked, monitored, reported consideration of legislation.

Met with Department of Health and Human Services' Offices of Women's Health Research to discuss future collaborations for educational forums on chronic diseases that affect women.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House  
Senate  
Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Tricia Brooks		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Form LD-2 (Rev. 06/98)

PAGE 5 of 5